Chief Operating Officer / Technology Lead at Synergy Global Health Foundation, Inc.
Answered 25 days ago
As an executive nurse with an MBA, I've seen firsthand how supply chain disruptions directly impact patient care, which is why the push to reshore API manufacturing is so important, but also more complex than it sounds. One of the biggest challenges is that API production was offshored for a reason. It's not just about lower costs. Countries like China and India have built entire manufacturing ecosystems over decades, with established supplier networks and economies of scale that are difficult to replicate locally. Even when production is brought back domestically, the supply chain often still depends on imported raw materials and intermediates, which limits how much resilience is actually gained. There are also regulatory hurdles. Changing manufacturing locations requires revalidation, compliance checks, and approvals, all of which take time and can delay production. On top of that, domestic manufacturing comes with significantly higher costs, labor, infrastructure, and regulatory compliance, which makes it hard for companies to justify the shift without sustained incentives. Ultimately, reshoring APIs isn't just about building facilities; it's about rebuilding an entire supply chain ecosystem. That's a long-term investment, not a quick fix.
Reshoring the API production is one of such concepts that sound simple on paper but becomes complicated rapidly once you start to do it. The political intent is, the money-discussion is, except the disjuncture between pronouncing a reshorcing venture and creating commerce-sized APIs inside the nation is huge. The first issue is merely elementary chemistry facilities. Many of the starting materials and intermediate that enter APIs are still only made in few countries mostly India and China. Thus, you may establish a brand new plant in the U.S. or Europe, but you still have to rely on the same supply chains to source raw materials. You have got one more link of the chain closer to the house, but you have not literally fixed the vulnerability. Real independence would be reshoring a number of layers of production and that is a far larger and even more costly task than most individuals are aware of. Then there's the talent issue. The laborer force that is familiar with operating these processes on a large-scale basis has been vested abroad over the decades. Constructing the facility is one thing, but filling the place with experienced personnel is an entirely different issue. It does not happen in months but years of training. The other elephant in the room is cost. Economics was the reason the manufacturing was out-sourced. The profit margins in generic drug manufacturers are so low and local manufacturing costs are much higher. The government subsidies and incentives can help bridge that divide but they are not lasting and companies are hardly willing to make 20 year long investments based on policies that can potentially change every election cycle. There is an additional layer of regulatory timelines. A new manufacturing site has to be approved and validated over a few years of paperwork, checking and qualifying of the processes. It is not a case of throwing the switch and getting on with it. Even well-funded reshoring processes will be slowed down by that timeline. I believe reshoring will occur at a slow pace in specific regions especially of APIs considered vital to national security or the drugs that have experienced extreme shortage. However, the notion that we are going to widely revert to the manufacturing of APIs an onshore basis in the not too distant future is not in keeping with the fact that such supply chains are very sophisticated and intricate.
Reshoring APIs sounds straightforward at a policy level, yet the friction shows up in the operational details that are hard to replicate quickly. Cost is part of it, since established manufacturing hubs benefit from decades of scale, supplier proximity, and lower input costs, but the deeper challenge is the supporting ecosystem. API production depends on specialized raw materials, experienced technical labor, and tightly coordinated quality systems that have been built over time, not assembled overnight. At AS Medication Solutions, the downstream impact of this complexity is visible when supply timelines shift or sourcing options narrow, even slightly. A delay at the manufacturing level can ripple through coordination efforts and affect how reliably clients receive what they need. There is also a regulatory layer that slows progress. Facilities must meet strict compliance standards before they can operate at scale, and that process is both time intensive and capital heavy. Even when investment is available, aligning infrastructure, workforce, and compliance at the same pace is difficult. The result is that reshoring moves forward in pockets rather than sweeping change, which explains why expectations have outpaced reality so far.